LYCALycia Therapeutics
临床阶段生物技术公司，利用LYTAC平台降解致病胞外蛋白。
$18发行价
$317M融资额
$30首日收盘
66.67%首日表现
临床阶段生物技术公司，利用LYTAC平台降解致病胞外蛋白。
公司简介（来源：StockAnalysis）
Lycia Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases. By leveraging our proprietary LYTAC (Lysosomal Targeting Chimera) platform, we have developed a pipeline of therapeutic candidates with the potential to provide deep and durable elimination of extracellular proteins that are inadequately addressed by currently available therapies. ...
51CFO 判断：需具备早期生物科技IPO财务建模、FDA/CDER沟通经验及平台型管线估值能力。
管理层与创始团队详情以 SEC 招股书披露为准
你的公司需要这样的 CFO 吗？
51CFO 是专注美股市场的投行团队：赴美 IPO、借壳上市、壳公司买卖、SPAC 与 De-SPAC、SEC 申报与上市后再融资，从架构到敲钟一条龙操盘。免费 30 分钟上市路径诊断，24 小时内回复。
预约咨询